Developer docs
API playgroundTry for free, no card

Search company profiles

Orum Therapeutics

Full company profile

uuid00021q6

Namestring
Orum Therapeutics
Legal namestring
Orum Therapeutics, Inc.
Websiteurl
orumrx.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Orum Therapeutics is a clinical-stage biotechnology company developing degrader-antibody conjugates (DACs), a therapeutic modality that combines proprietary molecular glue degrader payloads (notably GSPT1 degraders such as SMol006) with tumor-targeting antibodies connected via β-glucuronide cleavable linkers. Its Dual-Precision Targeted Protein Degradation (TPD²) platform uses the E3 ubiquitin ligase pathway to selectively degrade intracellular oncoproteins in defined cell populations, addressing cancers that are difficult to treat with conventional modalities — particularly acute myeloid leukemia (AML), including TP53-mutant disease. The lead proprietary candidate, ORM-1153, is a CD123-targeting DAC planned for IND submission in H2 2026. Orum also operates a complementary Targeted Protein Stabilization (TPS²) platform, with an initial Cbl-b inhibitor-PD-1 immuno-oncology conjugate program.

The company monetizes through a hybrid, transaction-based model. It licenses its TPD² platform for multi-target use (a July 2024 agreement with Vertex Pharmaceuticals in gene-editing conditioning: $15M upfront, up to $310M per target in option/milestone fees, plus tiered royalties) and divests individual drug programs outright (Bristol Myers Squibb acquired ORM-6151, an anti-CD33 GSPT1 degrader with FDA IND clearance, for $100M upfront plus up to $180M in milestones in November 2023). Orum completed its KOSDAQ IPO in February 2025 (KRX: 475830), raising approximately KRW 50 billion (~US$37M), and subsequently raised an additional ~US$100 million in convertible preferred stock in December 2025 led by KB Investment. The company operates dual headquarters in Daejeon, South Korea and Lexington, Massachusetts, and is led by founder-CEO Sung Joo Lee, Ph.D., with a recently deepened scientific and clinical leadership team.

Customers are exclusively large global pharmaceutical companies; Orum has no approved products and generates no recurring product revenue. The customer base is narrow (BMS, Vertex), making revenue inherently lumpy and event-driven. Recent operational moves — discontinuation of the ORM-5029 HER2 program in April 2025, nomination of ORM-1153 as new lead, AACR 2026 preclinical data presentation, and senior leadership additions — indicate active pipeline focus and preparation for first-in-human clinical execution.

Short descriptiontext

Orum Therapeutics is a clinical-stage Korean-American biotech developing degrader-antibody conjugates that combine targeted protein degraders with antibody delivery for oncology, monetizing via pharmaceutical licensing deals and pipeline asset sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, degrader-antibody conjugates, oncology drug development, antibody drug conjugates, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Asset/Program Acquisition
TypeOne Time License
Description

Orum receives upfront payments and milestone payments from pharmaceutical partners acquiring its drug programs. Bristol Myers Squibb acquired the ORM-6151 program for $100M upfront plus potential milestones of $180M total.

orumrx.com
2Platform Licensing and Option Agreements
TypeLicensing Royalties
Description

Orum licenses its TPD² technology platform to pharmaceutical partners for research, development, and commercialization. Vertex partnership includes $15M upfront payment plus up to $310M per target in option fees and milestones plus tiered royalties.

orumrx.com
3Future Product Revenue
TypeOne Time License
Description

Revenue from potential commercialization of proprietary degrader-antibody conjugate pipeline including ORM-1153 for AML and other programs.

orumrx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Orum Therapeutics is a clinical-stage biotechnology company developing degrader-antibody conjugates (DACs) that combine targeted protein degradation payloads with antibody-based cell-selective delivery for cancer treatment. Its proprietary TPD² (Dual-Precision Targeted Protein Degradation) and TPS² (Dual-Precision Targeted Protein Stabilization) platforms underpin a pipeline led by ORM-1153, a CD123-targeting DAC for acute myeloid leukemia. Orum monetizes its platform and programs primarily through licensing deals and program acquisitions with global pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ORM-1153 demonstrated approximately 1,000-fold higher potency than unconjugated degrader payload in preclinical studies
+3 more records
Product overview1 text field

Orum Therapeutics is a clinical-stage biotech pioneering degrader-antibody conjugates (DACs) through its Dual-Precision Targeted Protein Degradation (TPD²) platform and Targeted Protein Stabilization (TPS²) approach. The company's lead pipeline includes ORM-1153 (CD123-targeting GSPT1 degrader for AML, advancing toward IND filing in H2 2026) and earlier-stage programs in solid tumors. Orum has partnered with Vertex for gene editing applications and previously sold its ORM-6151 program to Bristol Myers Squibb. The technology combines proprietary degrader payloads with tumor-targeting antibodies to selectively degrade intracellular proteins via the E3 ubiquitin ligase pathway.

Product and service4 records
1ORM-1153
CategoryDrug Candidate (Degrader-Antibody Conjugate)
Description

A CD123-targeting degrader-antibody conjugate designed to selectively deliver a proprietary GSPT1-degrading payload via a β-glucuronide cleavable linker for treatment of acute myeloid leukemia and other CD123-positive hematological malignancies. Engineered for high internalization efficiency and reduced Fc-gamma receptor interactions.

2TPD² (Dual-Precision Targeted Protein Degradation) Platform
CategoryTechnology Platform (Licensable)
Description

Proprietary platform combining targeted protein degrader payloads with antibody-based cell-selective delivery, leveraging the E3 ubiquitin ligase pathway to degrade intracellular target proteins. Licensed to Vertex Pharmaceuticals in July 2024 for development of targeted conditioning agents for gene editing.

3TPS² (Targeted Protein Stabilization) Platform
CategoryTechnology Platform (Immuno-Oncology)
Description

Dual-precision targeted protein stabilization approach using proprietary Cbl-b inhibitor payloads conjugated to antibodies to increase intracellular target protein levels in a cell-type-specific manner for oncology and immuno-oncology applications.

4Cbl-b Inhibitor–PD-1 Conjugate
CategoryPreclinical Drug Candidate
Description

Immuno-oncology preclinical program combining a proprietary Cbl-b inhibitor payload with an anti-PD-1 antibody (pembrolizumab conjugate) to simultaneously block PD-1/PD-L1 signaling and enhance T-cell activation.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-16
Description

Global multi-target license and option agreement for Orum's TPD² technology to develop novel DACs for targeted conditioning agents for gene editing. Orum receives $15 million upfront and up to $310 million per target in potential option fees and milestones plus tiered royalties.

2Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-06
Description

BMS acquired Orum's ORM-6151 program, a first-in-class anti-CD33 antibody-enabled GSPT1 degrader for AML. Orum received $100 million upfront payment and is eligible for milestone payments totaling up to $180 million. This validates Orum's TPD² platform approach.

orumrx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Arvinas is the pioneer in targeted protein degradation using PROTACs, with a clinically validated platform. Highly comparable to Orum as both develop degrader-based oncology therapeutics; Arvinas is more mature with partnered programs (with Pfizer, Bayer, Roche/Genentech) analogous to Orum's BMS/Vertex deals.

TypeDirect peer
Description

Kymera develops targeted protein degraders with a focus on immunology and oncology, including partnerships with Vertex and Sanofi. Closely comparable to Orum given shared TPD modality, oncology focus, and partnership-heavy business model.

TypeBroad incumbent
Description

ImmunoGen pioneered ADCs (Kadcyla, Elahere) and was acquired by AbbVie. Comparable as an established ADC player; broader and more mature than Orum, but represents the commercial endpoint Orum's platform aspires to.

TypeDirect peer
Description

C4 Therapeutics develops small-molecule targeted protein degraders (dTORs/MONODs) for oncology with partnerships including Biogen, Roche, and Calithera. Comparable to Orum as a clinical-stage TPD platform company.

TypeBroad incumbent
Description

Daiichi Sankyo is a global leader in ADCs (Enhertu, Datroway) partnered with AstraZeneca. Comparable to Orum as an ADC innovator but at much larger scale, representing both a partnership opportunity and a competitive threat.

TypeEmerging player
Description

Repare Therapeutics is a precision oncology company developing synthetic lethality-based therapeutics. Comparable to Orum as a clinical-stage oncology biotech of similar size; Orum's new board member Dr. Koehler was previously CMO at Repare.

TypeEmerging player
Description

Prelude Therapeutics develops small molecule targeted protein degraders and other precision oncology candidates. Comparable to Orum as a clinical-stage TPD company; Orum's VP Korea previously held senior roles at Prelude.

TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptide-based conjugates (Bicycles) for oncology, partnering with major pharma including Roche, Novartis, and Bayer. Comparable to Orum given shared targeted-conjugate modality and oncology focus; Orum's new board member Dr. Koehler was previously CMO at Bicycle.

TypeDirect peer
Description

Mersana develops next-generation antibody-drug conjugates including Dolasynthen and Immunosynthen platforms. Highly comparable to Orum as an ADC platform company with proprietary linker/payload technology; Orum's Head of Platform Tech joined from Mersana.

TypeEmerging player
Description

Bolt Biotherapeutics develops immune-stimulating antibody conjugates (ISACs). Comparable to Orum as a clinical-stage next-generation ADC platform company of similar size and stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orum Therapeutics

Oncology Biopharmaceuticalsorumrx.com

Orum Therapeutics is a clinical-stage Korean-American biotech developing degrader-antibody conjugates that combine targeted protein degraders with antibody delivery for oncology, monetizing via pharmaceutical licensing deals and pipeline asset sales.

What Orum Therapeutics does

Orum Therapeutics is a clinical-stage biotechnology company developing degrader-antibody conjugates (DACs), a therapeutic modality that combines proprietary molecular glue degrader payloads (notably GSPT1 degraders such as SMol006) with tumor-targeting antibodies connected via β-glucuronide cleavable linkers. Its Dual-Precision Targeted Protein Degradation (TPD²) platform uses the E3 ubiquitin ligase pathway to selectively degrade intracellular oncoproteins in defined cell populations, addressing cancers that are difficult to treat with conventional modalities — particularly acute myeloid leukemia (AML), including TP53-mutant disease. The lead proprietary candidate, ORM-1153, is a CD123-targeting DAC planned for IND submission in H2 2026. Orum also operates a complementary Targeted Protein Stabilization (TPS²) platform, with an initial Cbl-b inhibitor-PD-1 immuno-oncology conjugate program.

The company monetizes through a hybrid, transaction-based model. It licenses its TPD² platform for multi-target use (a July 2024 agreement with Vertex Pharmaceuticals in gene-editing conditioning: $15M upfront, up to $310M per target in option/milestone fees, plus tiered royalties) and divests individual drug programs outright (Bristol Myers Squibb acquired ORM-6151, an anti-CD33 GSPT1 degrader with FDA IND clearance, for $100M upfront plus up to $180M in milestones in November 2023). Orum completed its KOSDAQ IPO in February 2025 (KRX: 475830), raising approximately KRW 50 billion (~US$37M), and subsequently raised an additional ~US$100 million in convertible preferred stock in December 2025 led by KB Investment. The company operates dual headquarters in Daejeon, South Korea and Lexington, Massachusetts, and is led by founder-CEO Sung Joo Lee, Ph.D., with a recently deepened scientific and clinical leadership team.

Customers are exclusively large global pharmaceutical companies; Orum has no approved products and generates no recurring product revenue. The customer base is narrow (BMS, Vertex), making revenue inherently lumpy and event-driven. Recent operational moves — discontinuation of the ORM-5029 HER2 program in April 2025, nomination of ORM-1153 as new lead, AACR 2026 preclinical data presentation, and senior leadership additions — indicate active pipeline focus and preparation for first-in-human clinical execution.

Orum Therapeutics firmographics

Firmographics
Name
Orum Therapeutics
Legal name
Orum Therapeutics, Inc.
Website
https://orumrx.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Orum Therapeutics is a clinical-stage Korean-American biotech developing degrader-antibody conjugates that combine targeted protein degraders with antibody delivery for oncology, monetizing via pharmaceutical licensing deals and pipeline asset sales.
Ownership category
akta.pro rank

Orum Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Targeted protein degradation
  • Degrader-antibody conjugates
  • Oncology drug development
  • Antibody drug conjugates
  • Clinical-stage biotechnology

Where Orum Therapeutics is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Orum Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Asset/Program Acquisition: Orum receives upfront payments and milestone payments from pharmaceutical partners acquiring its drug programs. Bristol Myers Squibb acquired the ORM-6151 program for $100M upfront plus potential milestones of $180M total.
  2. Platform Licensing and Option Agreements: Orum licenses its TPD² technology platform to pharmaceutical partners for research, development, and commercialization. Vertex partnership includes $15M upfront payment plus up to $310M per target in option fees and milestones plus tiered royalties.
  3. Future Product Revenue: Revenue from potential commercialization of proprietary degrader-antibody conjugate pipeline including ORM-1153 for AML and other programs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Orum Therapeutics product offering

Product offering

Core offering

Orum Therapeutics is a clinical-stage biotechnology company developing degrader-antibody conjugates (DACs) that combine targeted protein degradation payloads with antibody-based cell-selective delivery for cancer treatment. Its proprietary TPD² (Dual-Precision Targeted Protein Degradation) and TPS² (Dual-Precision Targeted Protein Stabilization) platforms underpin a pipeline led by ORM-1153, a CD123-targeting DAC for acute myeloid leukemia. Orum monetizes its platform and programs primarily through licensing deals and program acquisitions with global pharmaceutical companies.

Product overview

Orum Therapeutics is a clinical-stage biotech pioneering degrader-antibody conjugates (DACs) through its Dual-Precision Targeted Protein Degradation (TPD²) platform and Targeted Protein Stabilization (TPS²) approach. The company's lead pipeline includes ORM-1153 (CD123-targeting GSPT1 degrader for AML, advancing toward IND filing in H2 2026) and earlier-stage programs in solid tumors. Orum has partnered with Vertex for gene editing applications and previously sold its ORM-6151 program to Bristol Myers Squibb. The technology combines proprietary degrader payloads with tumor-targeting antibodies to selectively degrade intracellular proteins via the E3 ubiquitin ligase pathway.

Differentiator

Problem solved

Functional benefit

Products and services

  • ORM-1153 A CD123-targeting degrader-antibody conjugate designed to selectively deliver a proprietary GSPT1-degrading payload via a β-glucuronide cleavable linker for treatment of acute myeloid leukemia and other CD123-positive hematological malignancies. Engineered for high internalization efficiency and reduced Fc-gamma receptor interactions.
  • TPD² (Dual-Precision Targeted Protein Degradation) Platform Proprietary platform combining targeted protein degrader payloads with antibody-based cell-selective delivery, leveraging the E3 ubiquitin ligase pathway to degrade intracellular target proteins. Licensed to Vertex Pharmaceuticals in July 2024 for development of targeted conditioning agents for gene editing.
  • TPS² (Targeted Protein Stabilization) Platform Dual-precision targeted protein stabilization approach using proprietary Cbl-b inhibitor payloads conjugated to antibodies to increase intracellular target protein levels in a cell-type-specific manner for oncology and immuno-oncology applications.
  • Cbl-b Inhibitor–PD-1 Conjugate Immuno-oncology preclinical program combining a proprietary Cbl-b inhibitor payload with an anti-PD-1 antibody (pembrolizumab conjugate) to simultaneously block PD-1/PD-L1 signaling and enhance T-cell activation.

Quantifiable outcome

  • ORM-1153 demonstrated approximately 1,000-fold higher potency than unconjugated degrader payload in preclinical studies
  • +3 more outcomes

Companies that use Orum Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Orum Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Orum Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Vertex PharmaceuticalscoreStrategic or Co-development Partner · 16 July 2024Global multi-target license and option agreement for Orum's TPD² technology to develop novel DACs for targeted conditioning agents for gene editing. Orum receives $15 million upfront and up to $310 million per target in potential option fees and milestones plus tiered royalties.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 6 November 2023BMS acquired Orum's ORM-6151 program, a first-in-class anti-CD33 antibody-enabled GSPT1 degrader for AML. Orum received $100 million upfront payment and is eligible for milestone payments totaling up to $180 million. This validates Orum's TPD² platform approach.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Orum Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arvinas: Arvinas is the pioneer in targeted protein degradation using PROTACs, with a clinically validated platform. Highly comparable to Orum as both develop degrader-based oncology therapeutics; Arvinas is more mature with partnered programs (with Pfizer, Bayer, Roche/Genentech) analogous to Orum's BMS/Vertex deals.
  • Kymera Therapeutics: Kymera develops targeted protein degraders with a focus on immunology and oncology, including partnerships with Vertex and Sanofi. Closely comparable to Orum given shared TPD modality, oncology focus, and partnership-heavy business model.
  • C4 Therapeutics: C4 Therapeutics develops small-molecule targeted protein degraders (dTORs/MONODs) for oncology with partnerships including Biogen, Roche, and Calithera. Comparable to Orum as a clinical-stage TPD platform company.
  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based conjugates (Bicycles) for oncology, partnering with major pharma including Roche, Novartis, and Bayer. Comparable to Orum given shared targeted-conjugate modality and oncology focus; Orum's new board member Dr. Koehler was previously CMO at Bicycle.
  • Mersana Therapeutics: Mersana develops next-generation antibody-drug conjugates including Dolasynthen and Immunosynthen platforms. Highly comparable to Orum as an ADC platform company with proprietary linker/payload technology; Orum's Head of Platform Tech joined from Mersana.

Broad incumbents

  • ImmunoGen (AbbVie): ImmunoGen pioneered ADCs (Kadcyla, Elahere) and was acquired by AbbVie. Comparable as an established ADC player; broader and more mature than Orum, but represents the commercial endpoint Orum's platform aspires to.
  • Daiichi Sankyo: Daiichi Sankyo is a global leader in ADCs (Enhertu, Datroway) partnered with AstraZeneca. Comparable to Orum as an ADC innovator but at much larger scale, representing both a partnership opportunity and a competitive threat.

Emerging players

  • Repare Therapeutics: Repare Therapeutics is a precision oncology company developing synthetic lethality-based therapeutics. Comparable to Orum as a clinical-stage oncology biotech of similar size; Orum's new board member Dr. Koehler was previously CMO at Repare.
  • Prelude Therapeutics: Prelude Therapeutics develops small molecule targeted protein degraders and other precision oncology candidates. Comparable to Orum as a clinical-stage TPD company; Orum's VP Korea previously held senior roles at Prelude.
  • Bolt Biotherapeutics: Bolt Biotherapeutics develops immune-stimulating antibody conjugates (ISACs). Comparable to Orum as a clinical-stage next-generation ADC platform company of similar size and stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Orum Therapeutics social profiles

Digital presence

Orum Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orum Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Orum Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orum Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orum Therapeutics

What does Orum Therapeutics do?

Orum Therapeutics is a clinical-stage biotechnology company developing degrader-antibody conjugates (DACs) that combine targeted protein degradation payloads with antibody-based cell-selective delivery for cancer treatment. Its proprietary TPD² (Dual-Precision Targeted Protein Degradation) and TPS² (Dual-Precision Targeted Protein Stabilization) platforms underpin a pipeline led by ORM-1153, a CD123-targeting DAC for acute myeloid leukemia. Orum monetizes its platform and programs primarily through licensing deals and program acquisitions with global pharmaceutical companies.

Is Orum Therapeutics a public or private company?

Orum Therapeutics is a public company. It is classified as public and is currently operating.

When was Orum Therapeutics founded?

Orum Therapeutics was founded in 2018. It employs 51 to 100 people.

Where is Orum Therapeutics based?

Orum Therapeutics is headquartered in Daejeon, South Korea, in the Asia region.

How does Orum Therapeutics make money?

Three revenue lines are on record. Asset/Program Acquisition is the primary driver. The others are platform Licensing and Option Agreements and future Product Revenue.

Who are Orum Therapeutics's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, C4 Therapeutics, Bicycle Therapeutics and Mersana Therapeutics. Broad incumbents are ImmunoGen (AbbVie) and Daiichi Sankyo. Emerging players are Repare Therapeutics, Prelude Therapeutics and Bolt Biotherapeutics.

Does Orum Therapeutics have an API?

No public API is recorded for Orum Therapeutics.

What industry is Orum Therapeutics in?

Orum Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingOrum Therapeutics Holds Extraordinary Shareholders MeetingOrum Therapeutics shareholders approved amendments to the articles of incorporation at an extraordinary general meeting on Oct. 23, 2026. They also approved appointments of Geoffrey Harris Meyerson as non-executive director and Peter Unnam Park as independent director, and passed separate resolutions to grant stock options.GlobeNewswireOrum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody ConjugateOrum Therapeutics announced the first patient has been dosed in a Phase 1 trial of ORM-1153, a CD123-GSPT1 degrader-antibody conjugate, for relapsed or refractory acute myeloid leukemia. The open-label dose-escalation study will assess safety, pharmacology, and preliminary antileukemic activity, with approximately 42 patients expected to be enrolled.BusinesskoreaKOSDAQ Pharma Stocks Plunge 10.5% in One Month, Worst Among Major SectorsKOSDAQ pharmaceutical stocks fell 10.51% in a month, the worst among major sectors, as funds shifted to AI and semiconductors. The sector's year-to-date decline widened to 36.65%, with Orum Therapeutics and ABL Bio among the worst performers. Analysts expect investors to become more selective, citing a postponed promotion and relegation system.Nate[Seoul Data Lab] 20 Popular Search Items Right After the Deadline: Nate NewsAs of 3:35 PM on the 21st, 13 of the top 20 Naver Securities search stocks rose, with Samsung Electronics leading at 274,000 won up 4.98%. Neosapience surged 243% to 34,300 won, while Orum Therapeutics fell 27.01% to 27,300 won. Trading volumes and values were also reported, with Samsung Electronics having the largest trading value.BioSpaceBMS scraps Orum’s targeted degrader after reviewing Phase 1 dataBristol Myers Squibb discontinued development of Orum Therapeutics' targeted degrader ORM-6151 after reviewing Phase 1 data. The deal, acquired for $100 million upfront with $80 million in milestones, ends further milestone payments, and Orum retains about $180 million in cash. Orum will focus R&D on its pipeline and DAC platform.The Pharma LetterBMS discontinues Orum-derived degrader-antibody conjugate after Phase I reviewBristol Myers Squibb discontinued development of ORM-6151, a degrader-antibody conjugate licensed from Orum Therapeutics for $100 million in 2023, after reviewing early clinical trial data. Orum disclosed the termination in a financial filing.FierceBiotechBMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 dataBristol Myers Squibb terminated its $100 million purchase of Orum Therapeutics' degrader-antibody conjugate ORM-6151 after reviewing phase 1 data. The decision deprived Orum of up to $80 million in milestones, and the program is one of several axed under CEO Christopher Boerner.Clinical Trials ArenaOrum to begin Phase I trial of ORM-1153 after FDA clearanceThe FDA approved Orum Therapeutics' IND for ORM-1153, a CD123-GSPT1 degrader-antibody conjugate, enabling a Phase I trial. The first-in-human study targets relapsed or refractory AML and other haematologic malignancies, with approximately 42 patients at US sites. The trial is expected to commence by the end of 2026.BioSpaceOrum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody ConjugateOrum Therapeutics announced FDA clearance of its IND application for ORM-1153, a CD123-GSPT1 degrader-antibody conjugate. The company plans to initiate a first-in-human Phase 1 study in relapsed or refractory AML and other hematologic malignancies by the end of 2026. The study will enroll approximately 42 patients initially.YahooOrum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody ConjugateOrum Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ORM-1153, a novel CD123-GSPT1 degrader-antibody conjugate. The company plans to initiate a first-in-human Phase 1 clinical study in patients with relapsed or refractory acute myeloid leukemia by the end of 2026.